Summary

The Federal Administrative Court ruled on February 12, 2026, that the Federal Office of Public Health (BAG) must fully disclose redacted contracts with pharmaceutical companies Moderna and Novavax for corona vaccine procurement. The court found that the BAG's reasons for secrecy – particularly the protection of trade secrets and future negotiating position – are insufficient. The BAG has 30 days to appeal to the Federal Court. The decision likely concerns information about vaccine prices, delivery terms, and liability exemptions.

People

Topics

  • Transparency and right to public information
  • Corona vaccine procurement
  • Administrative courts
  • Pandemic post-processing

Clarus Lead

The Federal Administrative Court rejected the BAG's insufficient secrecy justification and demands full transparency in vaccine contracts. The decision strengthens the right to public information and compels authorities to make state spending traceable. For taxpayers and parliamentary oversight, this means clarity about vaccine prices and delivery conditions – central to pandemic post-processing.

Detailed Summary

The Federal Administrative Court St. Gallen rejected the BAG's secrecy arguments as insufficient. The office justified the redactions with trade secrets of pharmaceutical corporations and potential disadvantages in future pandemic negotiations – a so-called slippery-slope argument. The court recognized: once a state publishes contracts, comparisons can be drawn anyway. The logic of negotiating weakness thereby becomes questionable itself.

The redactions likely concerned price information, delivery conditions, and liability clauses for vaccine injuries. The BAG may appeal to the Federal Court within 30 days. Should no appeal occur, the contracts must be published. SVP National Council member Remi Wiesmann welcomed the decision as a "victory for the public" and emphasized taxpayers' right to access information about state spending.

Key Statements

  • Right to transparency outweighs secrecy: The Federal Administrative Court found insufficient grounds for comprehensive redactions.
  • Negotiating position argument fails: The concern about future disadvantages does not justify concealing concluded contracts.
  • Pandemic post-processing requires facts: Public contracts enable critical debate about pricing and conditions.
  • Freedom of information law works: Persistent requests and legal remedies force administrative transparency.

Other News Items

Wind power utilization in Switzerland only 18 %: The Swiss Eol association described 2025 as a "good average wind year" – without providing figures. Inquiries revealed: wind turbines operated at only 18 % capacity; over 80 % of the time they stood practically idle. A press release with misleading rhetoric that obscures Switzerland's lack of wind power suitability.

RTS sports commentator mixes politics and reporting: A commentator criticized Israeli athletes' alleged political positions regarding Gaza and the Middle East conflict during a bobsleigh broadcast. RTS later deleted the contribution but defended it as "factually correct, but too long for a sports commentary" – a rationalization that conceals violations of neutrality.

Mass shooting in US state Rhode Island: A 56-year-old opened fire in an ice rink during a high school game. At least three dead, including the shooter's ex-wife and daughter. The alleged shooter took his own life. European media concealed that the perpetrator is a transgender woman – a pattern also evident in a Canadian case one week prior.

Critical Questions

  1. Data Quality & Sources: Which specific contracts does the court ruling concern – only Moderna and Novavax or other manufacturers as well? Are prices, discounts, and volume tiering part of the redactions?

  2. Conflicts of Interest & Independence: Who represented the BAG in negotiations (pharmaceutical lobbying vs. independent experts) and to what extent did this influence the secrecy strategy?

  3. Causality & Alternatives: Could the BAG still negotiate good conditions in future pandemics even with comparative data publicly available? Which countries already publish similar contracts?

  4. Implementation & Risks: Will published contracts trigger political campaigns about "overpayment," even if prices were rational in global crises? How does the BAG protect itself from lack of context in media reporting?

  5. Media Representation: Do mainstream media report proportionally on contract details after publication or selectively on individual criticism points?

  6. Parliamentary Oversight: Could Parliament have demanded access during the pandemic itself, rather than only retrospectively?

  7. International Comparability: Do Swiss conditions fundamentally differ from contracts of other countries (Denmark, Sweden, Australia), or is the outrage disproportionate?

  8. Transparency Timing: Why did a court have to enforce what the BAG could have published preemptively – particularly for pandemic post-processing?

Source Directory

Primary Source: Bern einfach – Podcast Episode 17.02.2026 – https://audio.podigee-cdn.net/2361247-m-d7bd992bbf14d4ebb9ce7b4e61c8d23b.mp3

Supplementary Sources (mentioned in transcript):

  1. Federal Administrative Court St. Gallen – Ruling Corona Vaccine Contracts (12.02.2026)
  2. 20 Minuten – Citation SVP National Council member Remi Wiesmann
  3. Nebelspalter – Climate and Energy Newsletter Alex Reichmuth (wind power research)
  4. Telegraph – Reporting Rhode Island incident

Verification Status: ✓ 17.02.2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 17.02.2026